Loading
A phase 1 trial of CUSP06 run by OnCusp Therapeutics, Inc., now recruiting.
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors is a phase 1 interventional study registered as NCT06234423 by OnCusp Therapeutics, Inc., with 263 participants planned, started 2024-02-09. Conditions recorded: Ovarian Cancer and Solid Tumor. Interventions recorded: CUSP06.
Shares Multitude Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Multitude Therapeutics and the tag pipeline.
Shares Ovarian cancer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ovarian cancer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ovarian cancer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ovarian cancer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ovarian cancer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ovarian cancer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/